000163879 001__ 163879
000163879 005__ 20240229133510.0
000163879 0247_ $$2doi$$a10.1158/1055-9965.EPI-20-0965
000163879 0247_ $$2pmid$$apmid:33008875
000163879 0247_ $$2ISSN$$a1055-9965
000163879 0247_ $$2ISSN$$a1538-7755
000163879 0247_ $$2altmetric$$aaltmetric:91779626
000163879 037__ $$aDKFZ-2020-02113
000163879 041__ $$aeng
000163879 082__ $$a610
000163879 1001_ $$aDashti, S Ghazaleh$$b0
000163879 245__ $$aAdiposity and endometrial cancer risk in postmenopausal women: a sequential causal mediation analysis.
000163879 260__ $$aPhiladelphia, Pa.$$bAACR$$c2021
000163879 3367_ $$2DRIVER$$aarticle
000163879 3367_ $$2DataCite$$aOutput Types/Journal article
000163879 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1617965136_25638
000163879 3367_ $$2BibTeX$$aARTICLE
000163879 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163879 3367_ $$00$$2EndNote$$aJournal Article
000163879 500__ $$a2021 Jan;30(1):104-113
000163879 520__ $$aBackground Adiposity increases endometrial cancer (EC) risk, possibly through inflammation, hyperinsulinemia, and increasing estrogens. We aimed to quantify the mediating effects of adiponectin (anti-inflammatory adipocytokine); interleukin-6, interleukin-1-receptor antagonist, TNF-receptor-1 and -2, and C-reactive protein (inflammatory status biomarkers); C-peptide (hyperinsulinemia biomarker); free estradiol and estrone (estrogen biomarkers) in the adiposity-EC link in postmenopausal women. Methods We used data from a case-control study within the European Prospective Investigation into Cancer and Nutrition. Eligible women had not had cancer, hysterectomy, diabetes, did not use oral contraceptives or hormone therapy, and were postmenopausal at recruitment. Mediating pathways from adiposity to EC were investigated by estimating natural indirect (NIE) and direct (NDE) effects using sequential mediation analysis. Results The study included 163 cases and 306 controls. The adjusted odds ratio (OR) for EC for BMI≥30vs.18.5≤BMI<25kg/m2 was 2.51 (95%CI 1.26-5.02). The ORsNIE were 1.95 (1.01-3.74) through all biomarkers (72% proportion mediated (PM)) decomposed as: 1.35 (1.06-1.73) through pathways originating with adiponectin (33%PM); 1.13 (0.71-1.80) through inflammation beyond [the potential influence of] adiponectin (13%PM); 1.05 (0.88-1.24) through C-peptide beyond adiponectin and inflammation (5%PM); and 1.22 (0.89-1.67) through estrogens beyond preceding biomarkers (21%PM). The ORNDE not through biomarkers was 1.29 (0.54-3.09). Waist circumference gave similar results. Conclusion Reduced adiponectin and increased inflammatory biomarkers, C-peptide, and estrogens mediated ~70% of increased odds of EC in women with obesity vs. normal weight. Impact If replicated, these results could have implications for identifying targets for intervention to reduce EC risk in women with obesity.
000163879 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000163879 588__ $$aDataset connected to CrossRef, PubMed,
000163879 7001_ $$00000-0001-7828-8188$$aEnglish, Dallas R$$b1
000163879 7001_ $$aSimpson, Julie A$$b2
000163879 7001_ $$00000-0002-7497-1681$$aKarahalios, Amalia$$b3
000163879 7001_ $$aMoreno-Betancur, Margarita$$b4
000163879 7001_ $$aBiessy, Carine$$b5
000163879 7001_ $$aRinaldi, Sabina$$b6
000163879 7001_ $$aFerrari, Pietro$$b7
000163879 7001_ $$00000-0003-4385-2097$$aTjonneland, Anne$$b8
000163879 7001_ $$aHalkjær, Jytte$$b9
000163879 7001_ $$00000-0003-0481-2893$$aDahm, Christina C$$b10
000163879 7001_ $$aVistisen, Helene Tilma$$b11
000163879 7001_ $$00000-0003-3363-6411$$aMenegaux, Florence$$b12
000163879 7001_ $$aPerduca, Vittorio$$b13
000163879 7001_ $$00000-0001-7157-419X$$aSeveri, Gianluca$$b14
000163879 7001_ $$aAleksandrova, Krasimira$$b15
000163879 7001_ $$00000-0002-0830-5277$$aSchulze, Matthias B$$b16
000163879 7001_ $$00000-0002-5758-9069$$aMasala, Giovanna$$b17
000163879 7001_ $$aSieri, Sabina$$b18
000163879 7001_ $$aTumino, Rosario$$b19
000163879 7001_ $$aMacciotta, Alessandra$$b20
000163879 7001_ $$aPanico, Salvatore$$b21
000163879 7001_ $$aHiensch, Anouk E$$b22
000163879 7001_ $$aMay, Anne M$$b23
000163879 7001_ $$aQuirós, J Ramón$$b24
000163879 7001_ $$aAgudo, Antonio$$b25
000163879 7001_ $$00000-0003-4817-0757$$aSánchez, Maria-Jose$$b26
000163879 7001_ $$aAmiano, Pilar$$b27
000163879 7001_ $$aColorado-Yohar, Sandra$$b28
000163879 7001_ $$00000-0001-8434-2013$$aArdanaz, Eva$$b29
000163879 7001_ $$00000-0003-1938-5038$$aAllen, Naomi E$$b30
000163879 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b31
000163879 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b32$$udkfz
000163879 7001_ $$aChristakoudi, Sofia$$b33
000163879 7001_ $$aTsilidis, Konstantinos K$$b34
000163879 7001_ $$aRiboli, Elio$$b35
000163879 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b36$$udkfz
000163879 7001_ $$aGunter, Marc J$$b37
000163879 7001_ $$00000-0002-9799-4421$$aViallon, Vivian$$b38
000163879 7001_ $$00000-0003-2716-5748$$aDossus, Laure$$b39
000163879 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-20-0965$$gp. cebp.0965.2020 -$$n1$$p104-113$$tCancer epidemiology, biomarkers & prevention$$v30$$x1538-7755$$y2021
000163879 909CO $$ooai:inrepo02.dkfz.de:163879$$pVDB
000163879 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b32$$kDKFZ
000163879 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b36$$kDKFZ
000163879 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000163879 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000163879 9141_ $$y2021
000163879 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2018$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-17
000163879 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER EPIDEM BIOMAR : 2018$$d2020-01-17
000163879 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000163879 980__ $$ajournal
000163879 980__ $$aVDB
000163879 980__ $$aI:(DE-He78)C020-20160331
000163879 980__ $$aUNRESTRICTED